Table 1.
Demographics and Baseline Characteristics of 379 Cancer Patients on Active Cancer Treatment (Received Chemotherapy Within 30 days of Their COVID-19 Diagnosis) Split by Those Who Were (n = 249) and Were Not Hospitalized (n = 130) Post-COVID 19 Diagnosis
| Characteristic | G-CSF NOT Given Outpatient N = 351 n (%) | G-CSF Given Outpatient N = 28 n (%) | Total N = 379 n (%) |
|---|---|---|---|
| Age, years | |||
| ≤49 | 87 (25%) | 7 (25%) | 94 (25%) |
| 50–59 | 89 (25%) | 7 (25%) | 96 (25%) |
| 60–69 | 88 (25%) | 7 (25%) | 95 (25%) |
| ≥70 | 87 (25%) | 7 (25%) | 94 (25%) |
| Sex | |||
| M | 167 (48%) | 13 (46%) | 180 (47%) |
| F | 184 (52%) | 15 (54%) | 199 (53%) |
| Race | |||
| White | 229 (65%) | 13 (46%) | 242 (64%) |
| Black | 59 (17%) | 6 (21%) | 65 (17%) |
| Asian | 23 (7%) | 2 (7%) | 25 (7%) |
| Other | 40 (11%) | 7 (25%) | 47 (12%) |
| Underlying cancer | |||
| Breast | 82 (23%) | 8 (29%) | 90 (24%) |
| Colorectal | 37 (11%) | 4 (14%) | 41 (11%) |
| Lung | 36 (10%) | 1 (4%) | 37 (10%) |
| Lymphoma | 26 (7%) | 4 (14%) | 30 (8%) |
| Prostate | 26 (7%) | 1 (4%) | 27 (7%) |
| Other∞ | 144 (41%) | 10 (36%) | 154 (41%) |
| Cytotoxic chemotherapy within 30 days | 202 (58%) | 25 (89%) | 227 (60%) |
| Clinical symptoms | |||
| Fever | 210 (60%) | 16 (57%) | 226 (60%) |
| Shortness of breath | 89 (25%) | 7 (25%) | 96 (25%) |
| Cough | 197 (56%) | 17 (61%) | 214 (56%) |
| Diarrhea | 63 (18%) | 9 (32%) | 72 (19%) |
| Hospitalization post-GCSF use | |||
| Was NOT hospitalized | 225 (78%) | 24 (86%) | 249 (66%) |
| Was hospitalized | 127 (36%) | 4 (14%) | 131 (34%) |
Other∞ :central nervous system cancers (ie, astrocytoma); genitourinary cancers (ie, bladder cancer); gynecologic malignancies (ie, cervical), acute (acute lymphoblastic leukemia), and chronic leukemias (chronic myeloid leukemia); plasma cell dyscrasias (ie, amyloidosis). Although there are no differences in rates of individual adverse events between case-control groups (patients that did and did not receive a G-CSF, respectively), there is a statistically significant difference in effect size of G-CSF administration on rates of inpatient hospitalization when incorporated as a time-dependent covariate in a survival analysis (Table 2).
Abbreviations: COVID-19, coronavirus disease 2019; G-CSF, granulocyte colony-stimulating factor.